BBLG logo

Bone Biologics Corp (BBLG)

$1.39

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BBLG

Market cap

$2495411

EPS

-1.16

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.908318

Price on BBLG

Previous close

$1.38

Today's open

$1.32

Day's range

$1.32 - $1.39

52 week range

$1.05 - $4.13

Profile about BBLG

CEO

Jeffrey Frelick

Employees

2

Headquarters

Burlington, MA

Exchange

NASDAQ Capital Market

Shares outstanding

1795260

Issue type

Common Stock

BBLG industries and sectors

Healthcare

Medical Equipment & Supplies

News on BBLG

Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash

news source

GlobeNewsWire • Jul 8, 2026

news preview

Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1

BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the Company reported in December 2025. The updated shelf life is supported by continued third-party stability data.

news source

GlobeNewsWire • May 19, 2026

news preview

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance

news source

GlobeNewsWire • Jan 8, 2026

news preview

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Milestone advances manufacturing readiness and supports long-term commercialization strategy Milestone advances manufacturing readiness and supports long-term commercialization strategy

news source

GlobeNewsWire • Dec 23, 2025

news preview

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologics' development of NB1 and to review our expected milestones for the coming year, including the anticipated com.

news source

Business Wire • Sep 4, 2025

news preview

Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and in.

news source

Business Wire • Sep 3, 2025

news preview

Bone Biologics Announces Closing of $5.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares o.

news source

Business Wire • Jun 30, 2025

news preview

Why Is Bone Biologics Stock Surging On Friday?

Bone Biologics Corporation BBLG stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro.

news source

Benzinga • Jun 27, 2025

news preview

Bone Biologics Announces Pricing of $5.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a.

news source

Business Wire • Jun 27, 2025

news preview

Bone Biologics Files Patent Application for Bone Regeneration Technology

BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #Bonebiologics--Bone Biologics files U.S. patent application for bone regeneration technology.

news source

Business Wire • Jun 27, 2025

news preview

¹ Disclosures

Get started with M1

Invest in Bone Biologics Corp

Open an M1 investment account to buy and sell Bone Biologics Corp commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BBLG on M1